SNSS Sunesis Pharmaceuticals Inc.

+0.03  (+5%)
Previous Close 0.68
Open 0.69
Price To Book -5.95
Market Cap 51,741,475
Shares 72,528,000
Volume 62,748
Short Ratio
Av. Daily Volume 997,159

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 update at EHA meeting June 15, 2019 - no partial responses.
Advanced B-Cell Malignancies
Phase 2 investigator sponosored trial initiated March 2016
Vosaroxin in combination with cytarabine - VITAL
Previously untreated acute myeloid leukemia (AML) cancer
Phase 2 updated data released June 2016
Vosaroxin in combination with decitabine
Older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) - cancer
Endpoint not met Oct 2014. Additional trials required.
Cancer - Acute myeloid leukemia AML

Latest News

  1. Options Traders Expect Huge Moves in Sunesis (SNSS) Stock
  2. Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting
  3. The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA
  4. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
  5. Edited Transcript of SNSS earnings conference call or presentation 8-May-19 8:30pm GMT
  6. Sunesis: 1Q Earnings Snapshot
  7. Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights
  8. What's in the Cards for Sunesis (SNSS) This Earnings Season?
  9. Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights
  10. Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank
  11. Four Healthcare Stocks Heating Up on Thursday
  12. Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference
  13. The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
  14. 5 Cancer-Fighting Stocks to Boost Portfolio Gains
  15. Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS)
  16. Will Sunesis Pharmaceuticals Continue to Surge Higher?
  17. Edited Transcript of SNSS earnings conference call or presentation 7-Mar-19 9:30pm GMT
  18. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
  19. Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences
  20. Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up